TESSERA DEFENSE AND HOMELAND
HLSQNYSE AMERICAN🏆 #5305 by market capEarnings Nov 11US Equity
$0.17▼ $0.03 (−15.95%)
Market closed · at closeTrack HLSQ
Get earnings, price moves & breaking news on Telegram
24h▼ 15.9%
7d▼ 36.2%
14d▼ 27.7%
30d▼ 59.1%
ytd▼ 99.1%
1y▼ 99.8%
🏦Market Cap
$474,747
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.17 – $0.19
- 52-Week Range
- $0.19 – $115.14
- Volume (shares)
- 11,407
- Avg Volume (shares)
- —
- Shares Outstanding
- 2.7M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
TESSERA DEFENSE AND HOMELAND
HLSQFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout TESSERA DEFENSE AND HOMELAND
Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Oct 2026
Latest News & Updates
News unavailable.